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Case presentation
A 65-year-old woman, first evaluated at New England Medical
Center approximately 4 years ago for hypertension, was found to have
glycosuria with a concomitant serum glucose level of 95 mg/dl. Serum
uric acid was 2.1 mg/dl, the serum phosphorus was 1.8 mg/dl, and the
patient had a hyperchioremic metabolic acidosis; the serum bicarbonate
was 16 mEq/liter. Serum protein electrophoresis revealed a small
monoclonal spike determined by immunoelectrophoresis to be a kappa
light chain. Urinary protein electrophoresis revealed the same monoclo-
nal light chain. Bone marrow biopsy and rectal biopsy were normal.
Four months after first being seen, the patient was admitted for a
percutaneous renal biopsy. Hematocrit, white blood cell count, and
platelet count all were within normal limits. Creatinine clearance was 59
cc/mm. Plain films of the skull, pelvis, and spine revealed no evidence
of myeloma. At the time of admission for the renal biopsy, she was
treated only with neutral phosphate, 2 tablets orally 4 times daily.
Physical examination revealed an elderly woman in no acute distress.
Blood pressure was 150/90 mm Hg. The pulse was 72 and regular.
Funduscopic examination was not performed. The question arose of
slight enlargement of the right lobe of the thyroid. No breast masses
were found. The lungs were clear. Cardiac examination was unremark-
able. There were 2+ pulses throughout without bruits. Neurologic
examination disclosed mild numbness to pinprick in the tips of all
fingers, but no other abnormalities. Urinalysis revealed a specific
gravity of 1.022; pH, 6; albumin, greater than 100 mg/dl; a trace of
sugar; and 10 to 15 white blood cells, 0 to 2 red blood cells, and 4 to 6
epithelial cells per high-power field. Electrocardiogram was unremark-
able save for nonspecific ST-T wave changes. Chest x-ray was within
normal limits. Sodium was 145 mEq/Iiter; potassium, 4.2 mEq/liter;
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chloride, 115 mEq/liter; bicarbonate, 18 mEq/liter; BUN, 15 mg/dl; and
serum creatinine, 1.1 mg/dl. Total protein was 6,5 g/dl; albumin, 4 g/dl;
calcium, 9.5 mg/dl; phosphorus, 2.6 mg/dl; and uric acid, 1.6 mgldl.
Alkaline phosphatase was 82 IU. Blood sedimentation rate was 10 mm/
hr. Renal scan showed a 9.3 cm right kidney and a 10.2 cm left kidney.
Blood flow to both the kidneys was normal by renal scan, but uptake
was decreased. Nerve conduction time at the right carpal tunnel was
within normal limits with no evidence of peripheral neuropathy. The
electromyogram was normal. Thoracic spine films revealed minimal
osteopenia without destructive changes. Percutaneous renal biopsy
revealed tubuloepithelial cell changes with multinucleated cells, giant
cells, and dedifferentiated epithelial cells. No evidence of glomerular
disease was present. Congo red stain was negative. Immunofluores-
cence revealed granular deposits of complement in the glomerular
mesangium, in the small arteries, and along tubular basement mem-
branes, Electron microscopy revealed the glomerular structure to be
intact, and no electron-dense deposits were identified; no diagnostic
intracytoplasmic crystals were identified.
In the 4-year interval since the patient was first examined, she has
continued to do reasonably well clinically. She has been treated with
oral neutral phosphate supplements only. When last examined, the
patient was asymptomatic and her blood pressure was 160/90 mm Hg.
Renal failure remained normal. Skeletal survey disclosed no evidence
of lytic lesions. Serum and urine immunoelectrophoresis was
unchanged.
Discussion
DR. LESLIE S. T. FANG (Associate Director, Dialysis Unit,
Massachusetts General Hospital, and Assistant Professor of
Medicine, Harvard Medical School, Boston, Massachusetts):
In 1845, Henry Bence Jones, a noted English pathologist, was
referred a patient with severe bone pain. The referring physi-
cian, a general practitioner named Dr. Thomas Watson, had
observed some unusual properties of the patient's urine:
Saturday, Nov. 1, 1845
Dear Dr. Jones,
The tube contains urine of very high specific gravity.
When boiled, it becomes slightly opaque. On addition of
nitric acid, it effervesces, assumes a reddish hue, and
becomes quite clear, but as it cools, assumes the consisten-
cy and appearance which you see. Heat reliquifies it. What
is it? [1]
At autopsy, the patient was found to have characteristic
changes of multiple myeloma [2].
Since the initial report in 1847, the term Bence Jones protein
has been used to designate a urinary protein that leaves solution
at approximately 56°C under certain conditions of pH and ionic
strength and returns to solution upon further heating to 100°C.
We now know that Bence Jones protein actually represents a
homogeneous population of immunoglobulin light chains of
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Fig. 1. Normal handling of light-chain proteins.
either kappa or lambda type and is the product of a presumed
single clone of plasma cells. The presence of light-chain pro-
teins in the urine is associated with a number of systemic
diseases and a variety of renal disorders.
I will use the interesting patient presented today as a spring-
board for a discussion of the spectrum of renal manifestations of
light-chain proteinuria, but first we will review the normal
metabolism of light chains, their measurement in urine, and the
differential diagnosis of light-chain proteinuria.
Renal handling of light-chain proteins
The two major classes of light-chain proteins, termed kappa
and lambda, are synthesized in bone marrow plasma cells. Each
major type can be further classified by the use of appropriate
antisera into several subtypes, four kappa and five lambda.
Amino-acid sequence studies of light chains reveal that the 107
or so amino acids of the carboxyl terminal are almost invariant
in sequence and thus this portion of the chain is called the
constant region. The amino terminal end of the light chain,
together with the heavy chain, is responsible for binding to
antigens. The amino terminal end varies in sequence and thus is
designated the variable region. Normally, minute amounts of
light chain can be detected in the serum in the monomeric (mw
22,000) or dimeric (mw 44,000) form. As much as 50 mg of free
light chains can be excreted daily. The light chains excreted by
normal individuals are heterogeneous, containing both kappa
and lambda chains.
The kidney is the major site of metabolism of light-chain
proteins [3—5]. Whereas complete immunoglobulins (mw
160,000 to 900,000) and heavy chains do not pass through the
normal glomerular filtration barriers, the small light chains pass
through freely. These filtered proteins, reabsorbed by proximal
tubular cells [3, 4], are catabolized there by lysozymal enzymes
[5]. This process is exceedingly efficient, and only a minute
amount of light-chain protein appears in the urine normally.
Metabolism depends on normal proximal tubular cell function
[6—81, and damage to these cells can result in increased excre-
tion of light-chain protein in the urine (Fig. 1). In diseases in
which the production of light-chain proteins is markedly in-
creased, the ability of the proximal tubules to reabsorb all the
Frequent association
Multiple myeloma
Waldenstrom' s macroglobulinemia
Amyloidosis
Less frequent association
Lymphoma
Leukemia
Rare association
Nonreticular neoplasms
Light-chain deposition disease
No detectable systemic diseases
(Idiopathic Bence Jones proteinuria)
filtered protein is exceeded, and light-chain proteins appear in
the urine in high concentrations in this setting as well.
After injection into mice, '311-labeled, human light-chain
proteins are rapidly cleared from the circulation. Ligating and
severing the ureters prolongs the disappearance time only
slightly, whereas removal of the kidneys greatly prolongs the
half-life of the light-chain proteins [9]. Studies of the metabo-
lism of light-chain proteins in multiple myeloma patients and in
patients with renal disease show that the catabolic rate corre-
lates with the serum creatinine [10].
Detection of urinary light-chain proteins
A number of tests are used to detect the presence of light-
chain proteins in the urine. Since the discovery of the unique
thermal properties of urinary light-chain proteins, the Putnam
heat test has been used as a screening method [11]. However,
standard heat tests are insensitive and can detect urinary light-
chain proteins only when the concentration exceeds 150 mg/dl.
False-positive tests have been noted in patients with mixed
connective tissue disease and in patients with chronic renal
failure [12]. The sulfosalicylic acid (Exton's reagent) test can
detect urinary light chains but, again, is relatively insensitive.
False-negative results are particularly common if the specific
gravity of the urine is less then 1.010 [12]. Albustix, which
detects albuminuria, cannot detect urinary light-chain proteins.
Indeed, in a patient with a negative Albustix test and a positive
sulfosalicylic acid test, light-chain proteinuria should be consid-
ered. Light-chain proteins in the urine can best be detected and
identified by immunoelectrophoresis with the use of monospe-
cific anti-kappa and anti-lambda sera; concentration of the urine
improves the results.
Differential diagnosis of light-chain proteinuria
The presence of light-chain proteins in the urine usually
denotes a systemic disease (Table 1). Light-chain proteinuria is
an important marker for monoclonal gammopathy and a variety
of lymphoproliferative diseases.
Light-chain proteinuria is most often associated with multiple
myeloma. Plasma cell myeloma represents a proliferation of a
single clone of plasma cells that often retain the capacity to
produce immunoglobulins. If more light chains than heavy
chains are produced, the excess light chains appear in the serum
and urine. In various series, light-chain proteinuria is detectable
in 47% to 70% of patients with multiple myeloma at some time
during the course of their disease [12]. The frequency of
occurrence of light-chain proteinuria depends on the type of
myeloma. In one series of 598 patients, light-chain proteinuria
Minute amounts of
circulating light
chain proteins
Filtered
Reabsorbed by
proximal tubular
cells
Table 1. Diseases associated with light-chain proteinuria
Catabolized
by lysozymal
enzymes
Minute amounts of
light chain proteins
in urine (<50 mg/day)
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was detected in 60% of patients with IgG myeloma, 71% of
patients with IgA myeloma, and 100% of patients with IgD
myeloma [13]. The 15% of patients with mycloma and only
monoclonal light chains in the serum uniformly have light-chain
proteinuria. The type of light chains excreted also depends in
part on the type of myeloma the patient has. Kappa light chains
are more common in IgG and IgA myeloma, whereas lambda
light chains are more prevalent in IgD myeloma and light-chain
disease [14].
Light-chain proteinuria is also common in WaldenstrOm's
macroglobulinemia; its prevalence ranges from 30% to 40%
[15]. Patients with WaldenstrOm's macroglobulinemia have a
plasma cell dyscrasia and they produce 1gM paraproteins.
Because of the tendency for 1gM to form a pentamer, patients
with the disease are much more likely to develop high serum
viscosity than are patients with multiple myeloma.
In primary amyloidosis, and in forms of amyloidosis associat-
ed with myeloma, the amyloid proteins are made of fibrillar
proteins derived from immunoglobulin light chains. When care-
fully sought, light-chain proteinuria is detected in as many as
92% of patients with primary amyloidosis [16]. The light-chain
proteins excreted in patients with amyloidosis usually are the
lambda type. In one study, 8 of 9 patients with amyloid-forming
proteins had lambda light-chain proteins [17].
Other neoplastic disorders also can account for light-chain
proteinuria. Abnormal amounts of monoclonal immunoglob-
ulins have been found in patients with malignant lymphoma [18]
and chronic lymphocytic leukemia [19]. Rarely, light-chain
proteinuria has been detected in patients with angioimmuno-
blastic lymphadenopathy [20], adenocarcinoma of the pancreas
[21], and medullary carcinoma of the thyroid [22].
A number of recent reports have brought attention to an
entity called light-chain deposition disease. Patients with this
disease have light-chain deposition in many organs, including
the kidneys, liver, and heart [23—27], as well as in the skin and
nervous system [23]. Proteinuria or renal insufficiency are the
most common presenting complaints [23]. Less commonly,
cardiac failure, rhythm disturbances, conduction abnormalities
[23] or hepatic dysfunction [23, 24] can be the presenting
symptoms. Two-thirds of patients with light-chain deposition
have myeloma or other lymphoplasmacytic proliferative dis-
eases (lymphoma, WaldenstrOm' s marcroglobulinemia) [23].
The remaining one-third of patients have no demonstrable
systemic illnesses. About one-half of patients with light-chain
deposition disease have light-chain proteinuria [23].
Idiopathic Bence Jones proteinuria, a diagnosis of exclusion,
is the least common cause of light-chain proteinuria. Benign
monoclonal gammopathy generally is characterized by a mono-
clonal serum peak of less than 3 gldl, normal serum albumin,
bone marrow plasma cells of less than 5%, no anemia, no lytic
bone lesions, and by definition no progression of these abnor-
malities for a minimum of 3 years [28, 29]. A few of these
patients have detectable light-chain proteinuria, but usually the
amount of proteinuria is negligible. In rare instances, however,
a significant amount of homogeneous light-chain proteinuria
may be found, and these patients are said to have idiopathic
Bence Jones proteinuria. Kyle, Maldonado, and Bayrd reported
2 patients who excreted more than 1 g of light-chain protein
daily for more than 7 years yet who had no evidence of
myeloma or other malignant diseases [30]. The patient de-
Table 2. Renal syndromes associated with light-chain proteinuria
Asymptomatic light-chain proteinuria
Proximal tubular dysfunction (Fanconi syndrome)
Distal tubular dysfunction
Combined light-chain nephropathy
Albuminuria
Acute renal failure
Chronic renal failure
scribed today has had light-chain proteinuria for 4 years without
evidence of systemic disease. The diagnosis of idiopathic light-
chain proteinuria is difficult to establish, however, because the
duration of follow-up required to confirm the diagnosis has not
been defined. The existence of light-chain proteinuria for 7
years prior to the diagnosis of myeloma has been described in a
number of patients [31, 32].
Renal manifestations of light-chain proteinuria
Because light-chain proteins have a variety of effects on the
kidney, light-chain proteinuria produces many renal manifesta-
tions (Table 2). I will review the clinical data now and the
underlying pathophysiology later.
Asymptomatic light-chain proteinuria. As I mentioned earli-
er, normal individuals can excrete minute amounts of light-
chain protein, usually in concentrations of less than 6 mgldl of
urine. A significant excretion of light-chain proteins is often
associated with renal dysfunction. Some patients have no
demonstrable renal functional abnormalities, although they
excrete a large amount of light-chain protein (idiopathic light-
chain proteinuria). In the 2 patients described by Kyle et al,
creatinine clearances and renal tubular function remained nor-
mal during the 7 years of follow-up [30]. Many patients with
multiple myeloma have no demonstrable renal functional abnor-
malities despite persistent light-chain proteinuria. In virtually
every series, 10% to 40% of patients with light-chain proteinuria
have had normal renal function [33—39]. The amount, type
(lambda versus kappa), and duration of light-chain excretion do
not appear to correlate with renal dysfunction in these patients.
These findings have led many investigators to conclude that
other factors in addition to light-chain excretion must be
important in the development of renal dysfunction in patients
with multiple myeloma.
Renal dysfunction is quite uncommon in patients with Wal-
denstrom's macroglobulinemia. When renal impairment is pre-
sent, it seldom is due to light-chain precipitation in the tubules.
Instead, renal insufficiency usually is secondary to amyloidosis
[40], lymphocytoid cell infiltration [41], intraglomerular 1gM
deposits [42], thrombi secondary to increased viscosity [42], or,
rarely, immunologically mediated glomerulonephritis [43].
The occasional patient with idiopathic light-chain proteinuria
requires close follow-up; one must always suspect the develop-
ment of multiple myeloma. Light-chain proteinuria can precede
clinically apparent myeloma for as much as 16 years [30].
Patients with multiple myeloma and asymptomatic light-chain
proteinuria should have chemotherapy directed towards the
myeloma. Light-chain proteinuria often subsides with control of
the plasma cell dyscrasia. Patients with WaldenstrOm's macro-
globulinemia and light-chain proteinuria usually require treat-
ment only if hyperviscosity syndromes develop. Various thera-
pies for patients with these and other renal syndromes occur-
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Table 3. Management of the renal syndromes associated with
light-chain proteinuria
Syndrome Treatment
Asymptomatic light-chain proteinuria
Idiopathic No therapy
Multiple myeloma Chemotherapy
WaldenstrOm's macroglobulinemia No therapy
Proximal tubular dysfunction
(Fanconi syndrome)
Associated with myeloma Chemotherapy
Not associated with myeloma No therapy
Distal tubular dysfunction
Distal RTA NaHCO3
Nephrogenic DI Hydrochlorothiazide
Combined light-chain nephropathy
Same as above
Proteinuria
Light-chain proteinuria Chemotherapy if myeloma
is present
Tubular proteinuria No therapy
Glomerulonephritis Conservative management
of nephrotic syndrome
Amyloidosis ?? Colchicine
Acute renal failure
Multiple myeloma Chemotherapy
Avoid dehydration
Avoid contrast studies
Treat hypercalcemia
Treat infection
Treat hyperuricemia
Correct obstructive
uropathy
?? Plasmapheresis
Dialysis
Waldenstrom's macroglobulinemia Plasmapheresis for
hyperviscosity
ring with light-chain proteinuria are listed in Table 3.
Proximal tubular dysfunction. Proximal renal tubular dys-
function (the Fanconi syndrome) in the absence of renal insuffi-
ciency has been reported in at least 30 patients with light-chain
proteinuria [44—56]. The prevalence probably would be higher if
all patients with light-chain proteinuria were tested for renal
tubular dysfunction. Varying degrees of glucosuria, aminoacid-
uria, phosphaturia, lysozymuria, and proximal renal tubular
acidosis can occur in these patients.
In most cases, the proximal tubular dysfunction precedes by
months or years any overt manifestation of myeloma or amy-
loidosis [49, 50, 55, 56]. Myeloma preceding the development of
the Fanconi syndrome has not been reported. In some in-
stances, as in the patient presented today, tubular dysfunction
and light-chain proteinuria can exist for many years without
clinical evidence of myeloma.
Although light-chain proteinuria is present in these patients
with the Fanconi syndrome, serum monoclonal gammopathy
may be absent. It is therefore important that immunoelectro-
phoretic studies be performed on the urine as well as on the
serum in adult patients with the syndrome. The Fanconi syn-
drome is almost exclusively associated with kappa light-chain
proteinuria [50, 52, 55, 56]. Only 2 patients have been reported
to have lambda light-chain proteinuria and the Fanconi syn-
drome [57, 58]. The reason for this peculiar observation is not
known.
Most authors believe that the proximal tubular dysfunction is
directly due to the adverse effect of light-chain proteins on the
proximal tubular cells. Renal tissue in these patients shows
crystalline deposits in the convoluted proximal tubular cells;
these crystals are similar to those in myeloma cells obtained
from the bone marrow. Interstitial infiltrates and fibrosis as well
as proximal tubular atrophy also are prominent [52, 54, 55].
Gonick described recurrence of the Fanconi syndrome in a
renal allograft in a patient with light-chain disease [59]. Patients
with light-chain proteinuria and proximal tubular dysfunction
should be treated with chemotherapy if there is associated
myeloma. Proximal tubular dysfunction per se usually does not
require therapy. Proximal renal tubular acidosis and tubular
proteinuria usually are mild (see Table 3).
Distal tubular dysfunction. Some patients with light-chain
proteinuria have distal tubular dysfunction manifested by distal
renal tubular acidosis or, rarely, nephrogenic diabetes insipi-
dus. Detailed studies of distal tubular function have not been
carried out in many patients with light-chain proteinuria, but the
prevalence of functional impairment seems quite high. In one
series of 35 consecutive patients with multiple myeloma, uri-
nary acidification was abnormal in 14 [57]. Of these 14, 13 had
light-chain proteinuria. In the same study, a high prevalence of
defects in urinary concentration also was observed. Impairment
of urinary concentrating ability was more severe in patients
with light-chain proteinuria. Nephrogenic diabetes insipidus has
been reported in one patient with WaldenstrOm's macroglobu-
linemia [60].
Myeloma with concurrent distal renal tubular acidosis also
should be treated with chemotherapy. Patients with distal RTA
may have significant acidosis and may require sodium bicarbon-
ate therapy. Patients with severe polyuria may benefit from low
doses of thiazide diuretics.
Combined proximal and distal tubular dysfunction (light-
chain nephropathy). A few patients with light-chain proteinuria
have manifested multiple abnormalities of both proximal and
distal tubule transport mechanisms, including the Fanconi
syndrome, nephrogenic diabetes insipidus, and distal tubular
acidosis. Smithline, Kassirer, and Cohen described a 51-year-
old patient with polydipsia and polyuria who had nephrogenic
diabetes insipidus and concomitant aminoaciduria, phosphatu-
na, and uricosuria [61]. An ammonium chloride loading test
revealed distal tubular acidosis. The patient excreted 149 mg of
kappa light chain per 24 hours. At the time there was no
evidence of multiple myeloma or amyloidosis. The authors
believed that the concurrence of proximal tubular dysfunction,
distal tubular dysfunction, and light-chain proteinuria repre-
sented a unique syndrome, which they called "combined light-
chain nephropathy."
DeFronzo, Cooke, and Humphrey described one patient with
IgG myeloma who had glucosuria, generalized aminoaciduria,
hypophosphatemia, hypouricemia, diminished concentrating
ability, and distal renal tubular acidosis [57]. This patient
excreted 70 mg of lambda light chain per 24 hours.
The patient under discussion today clearly has combined
light-chain nephropathy. She has clear-cut proximal and distal
tubular dysfunction as well as light-chain proteinuria with no
demonstrable lymphoproliferative disease.
Albuminuria. Patients with light-chain proteinuria often have
varying degrees of albuminuria with or without the Fanconi syn-
drome secondary to tubular dysfunction [44, 46, 47]. In these
patients the daily albumin excretion is usually less than 3 g.
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Patients with low-grade albuminuria need therapy only if
associated diseases are present. Heavy albuminia, with symp-
toms and signs of nephrotic syndrome, in patients with light-
chain proteinuria usually is due to amyloidosis. Amyloidosis
complicates multiple myeloma in 5% to 15% of patients and
invariably is associated with light-chain proteinuria [16, 35, 62—
64], usually of the lambda type. Amyloidosis is particularly
likely in patients with IgD myeloma [62], light-chain disease
[40], and Waldenström's macroglobulinemia [62]. Primary amy-
loidosis also is associated with a high incidence of light-chain
proteinuria [65, 66].
In the kidney, amyloid deposition can involve blood vessels,
interstitium, tubular basement membrane, and glomeruli. When
glomeruli are involved, severe albuminuria and nephrotic syn-
drome can result. Because heavy albuminuria is uncommon in
patients with light-chain proteinuria, amyloidosis should be
suspected in patients presenting with the nephrotic syndrome.
Patients with significant albuminuria and symptoms of nephrot-
ic syndrome may require salt restriction and judicious use of
diurectics. Patients with documented amyloidosis may benefit
from a trial of colehicine. Colchicine has been shown to be
effective prophylactically in familial Mediterranean fever, but it
has only been sporadically tried in established amyloidosis.
In rare instances, renal biopsy in patients with light-chain
proteinuria reveals glomerular lesions that can cause albumin-
uria. Glomerulonephritis also has been reported in patients with
WaldentrOm's macroglobulinemia [42, 43, 62] and benign mono-
clonal gammopathy [67, 68]. It is clear, however, that the light-
chain proteins are not involved in the pathogenesis of these
lesions.
Patients with light-chain deposition disease can manifest
albuminuria and nephrotic syndrome [23]. Renal biopsies show
light-chain deposition along the tubular and glomerular base-
ment membrane as well as in the mesangium [23]. Occasionally,
nodular lesions similar to those in Kimmelstiel-Wilson glomeru-
lopathy can be seen [251. In addition to proteinuria, progressive
renal insufficiency is common in light-chain deposition disease
[23]. Therapy with alkylating agents and prednisone appears to
be effective in preventing renal functional deterioration [23].
Acute renal failure. Acute renal failure occurs in 8% to 30%
of patients with multiple myeloma [69—71] and can occur both in
patients with previously normal renal function and in patients
with varying degrees of chronic renal insufficiency. In myeloma
patients, acute renal failure usually develops only when light-
chain proteinuria is present. A number of factors are associated
with the precipitation of acute renal failure, however (Table 4).
Dehydration is important in the precipitation of acute renal
failure in many patients [71—75]. Rees and Waugh, in reviewing
22 cases of acute renal failure in patients with multiple myelo-
ma, found clinical evidence of dehydration in all but one patient
[75]. They believe that dehydration and aciduria favor the
precipitation of light-chain tubular casts. DeFronzo and co-
workers reviewed the clinical course of 14 myeloma patients
who developed acute renal failure [71]; 4 of these patients had
clinical evidence of dehydration. Ganeval and colleagues re-
viewed the clinical course of 65 patients with myeloma and
reported acute renal failure in 30% [70]. Dehydration frequently
contributed to the acute renal failure in these patients.
Hypercalcemia is another important cause of acute renal
failure in myeloma. In the 14 patients reported by DeFronzo et
Table 4. Factors associated with acute renal failure in patients with
multiple myeloma
Common precipitating factors
Dehydration
Hypercalcemia
Contrast-induced acute renal failure
Less common precipitating factors
Nephrotoxic drugs
Infection
Rare causes of acute renal failure
Hyperuricemia
Nephrolithiasis
Hyperviscosity
Myeloma cell infiltration
Intraglomerular deposits of immunoglobulins
al [71], 9 had serum calcium concentrations greater than 11 mgI
dl. In 6, the calcium concentration was 15 mg/dl or greater.
Four of the patients recovered renal function following success-
ful treatment of hypercalcemia. Hypercalcemia was present in
20% to 30% of patients with acute renal failure in other series
[70, 76]. Hypercalcemia in these patients probably impairs the
renal concentrating ability, thus leading to dehydration and
promoting the precipitation of light-chain proteins in the renal
tubules. The likelihood of dehydration is increased substantially
by the nausea, vomiting, and altered mental status associated
with hypercalcemia. Hypercalciuria also can exert a direct
nephrotoxic effect and thus cause tubular degeneration and
necrosis [77].
The risk of administration of contrast agents to patients with
multiple myeloma is not clearly defined. Some authors [78—92]
believe that contrast studies are contraindicated and "may
prove to be disastrous" [86]. Others think that contrast studies,
particularly those that use the more soluble tri-iodinated con-
trast agents, are relatively safe [93—98]. The uncertainty may be
explained by the multiple factors that can precipitate acute
renal failure in patients with myeloma. Furthermore, many
patients with multiple myeloma may have pre-existing renal
insufficiency, a factor known to be important in the develop-
ment of contrast-induced acute renal failure. No prospective
studies have examined the incidence of acute renal failure after
contrast studies in patients with multiple myeloma.
As in other patients, nephrotoxic drugs also can precipitate
acute renal failure in patients with myeloma. Although the 14
patients reported by DeFronzo et al constitute a small sample,
drug-induced nephrotoxicity might have contributed to the
development of acute renal failure in 3 [71].
The decreased production of normal immunoglobulins as well
as compromised immune responses make patients with multiple
myeloma particularly susceptible to infection. Urinary stasis
secondary to tubular blockage from protein casts or stones can
contribute further to the development of pyelonephritis. Acute
pyelonephritis, found in 5% to 20% of patients with multiple
myeloma at autopsy [67, 99], might contribute to the acute renal
functional deterioration.
Despite the high incidence of light-chain proteinuria in pa-
tients with WaldenstrOm's macroglobulinemia, acute renal fail-
ure is rarely reported [100, 101]. Renal insufficiency is due to
occlusive macroglobulin deposits within the intraglomerular
capillaries in some cases [100], and to interstitial infiltration
with plasma or lymphoid cells in others [101]. Tubular obstruc-
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tion from light-chain protein casts has not been reported in
patients with Waldenström' s macroglobulinemia.
In patients with multiple myeloma and light-chain protein-
uria, one must take care to avoid precipitating acute renal
failure. The patient should be adequately hydrated, particularly
prior to initiation of chemotherapy. Hypercalcemia should be
aggressively treated with saline diuresis, mithramycin, steroids,
and calcitonin. Hyperuricemia should be managed with allopu-
rinol and diuresis. Nephrolithiasis and urinary tract infections
should be promptly treated. Although not absolutely conclu-
sive, the large numbers of individual case reports of docu-
mented contrast-induced acute renal failure in the absence of
other known causes of acute renal failure make a cause-and-
effect relationship likely. Contrast studies thus should be per-
formed judiciously in patients with multiple myeloma.
In patients with established renal failure, peritoneal dialysis
[1021 or hemodialysis can be used [71, 103, 1041. Unfortunately,
the prognosis for myeloma patients with acute renal failure is
poor despite aggressive intervention [71, 103, 104]. In several
series, renal function recovered in only a small fraction of the
patients, and a large fraction of the patients died within a few
months [71, 103, 1041.
Plasmapheresis occasionally has been effective in the treat-
ment of acute renal failure [105—107]. Feest, Burge, and Cohen
reported a patient with severe renal failure treated with forced
diuresis, peritoneal dialysis, and plasmapheresis who had excel-
lent recovery of renal function that was maintained for 9 months
[105]. Locatelli et al reported that renal failure was reversed in 4
consecutive patients with myeloma and acute renal failure
treated with steroid "pulses" and plasmapheresis [106]. Renal
function was maintained during 6 to 26 months of follow-up.
Misiani et al reported a similar result in 3 patients [107]. This
therapy is based on the concept that removal of light chains by
plasmapheresis may be of therapeutic value. Not all patients
treated with plasmapheresis have renal recovery, however.
Sieberth and coworkers used plasma separation to treat 2
myeloma patients who had hyperproteinemia and acute renal
failure, and were able to reverse the hyperproteinemia but not
the renal insufficiency [108].
Chronic rena/failure. In contrast to rare occurrences of acute
renal failure, chronic renal failure is quite common in patients
with light-chain proteinuria, particularly those with multiple
myeloma. Chronic renal failure develops in 30% to 60% of
patients with myeloma [31—39, 109—ill]. The prevalence of
renal failure is much higher in patients with light-chain protein-
uria, and the severity of renal failure correlates with the light-
chain protein excretion rate [109]. The prevalence of renal
insufficiency is also in part related to the type of myeloma.
Renal failure is most common in patients with light-chain
disease; renal failure occurs in 14% of patients with IgG
myeloma, 33% of patients with IgA myeloma, 60% of patients
with IgD myeloma, and in an unknown percentage of patients
with IgE disease [109].
Renal failure is second only to infection as the major cause of
death in patients with myeloma. Despite aggressive therapy,
patients with renal failure have a considerably worse prognosis
than do myeloma patients without renal insufficiency.
Many factors contribute to the development of chronic renal
failure in patients with multiple myeloma (Table 5). Some of the
factors associated with the development of acute renal failure
Table 5. Factors associated with chronic renal failure in patients with
multiple myeloma
also play important roles in the pathogenesis of chronic renal
failure. The most important pathologic finding in patients with
chronic renal insufficiency is "myeloma kidney," characterized
by intratubular deposits of glassy, eosinophilic, lamellated
casts. Varying degrees of giant cell reaction, tubular dilation
and atrophy, and interstitial fibrosis also occur. A close rela-
tionship between myeloma kidney and the presence of light-
chain proteinuria seems to exist, but instances of cast formation
in the absence of light-chain proteinuria have been reported
[1101.
Hypercalcemia plays an important adjunctive role in the
development of chronic renal insufficiency. Kyle and Elveback
noted that severe hypercalcemia was present in 24% of patients
with renal failure but in only 1% of patients with normal renal
function [76]. Acute and chronic pyelonephritis, as well as
nephrotoxic drugs, also may contribute to renal parenchymal
injury.
Less frequently, amyloidosis, uric acid nephropathy, and
calcium and uric acid nephrolithiasis may contribute to renal
functional deterioration. Plasma cell infiltration can occur,
although it is usually of minor degree and is unlikely to result in
significant renal dysfunction.
Chronic maintenance dialysis and transplantation have been
performed successfully in patients with end-stage renal disease
secondary to multiple myeloma. Maintenance hemodialysis
relieves uremic symptoms and extends life [103, 112, 113]. The
patients are at higher risk for infection, particularly of vascular
accesses. Generally, the patients do well on hemodialysis until
their myeloma progresses. In the series reported by Johnson et
al, 8 of 11 patients had reasonable clinical improvement for an
extended period [103]. Of interest is the report of a 61-year-old
woman with chronic renal failure who was dialysed for 16
months and had enough reversal of renal insufficiency to permit
her to discontinue dialysis [114]. Successful renal transplanta-
tion has been reported in a few patients [115] and is a reasonable
option in the patient with clinical evidence of prolonged
remission.
Pathophysiology
It is clear that the presence of light-chain proteins in the urine
leads to a variety of renal syndromes. Some light-chain proteins
appear to have no effect on renal function. Others cause
proximal or distal tubular dysfunction. Some are quite nephro-
toxic, leading to acute and chronic renal failure, and some lead
to amyloidosis. A number of studies have examined the possi-
ble pathogenetic mechanisms in the development of these renal
syndromes.
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Fig. 2. Pathogenesis of proximal tubular dysfunction.
Proximal renal tubular dysfunction. Most patients with the
Fanconi syndrome and light-chain proteinuria excrete kappa
light-chain proteins (50, 52, 55, 56]. As I noted, renal tissue
examination in some of these patients has revealed crystalline
bodies similar to those found in myeloma cells in the proximal
tubules [52, 54, 55].
Clyne et al injected large amounts of urine from a patient with
IgA myeloma, renal failure, and heavy kappa light-chain pro-
teinuria into rats [116]. Following injection, light microscopy
disclosed large numbers of droplets in the proximal tubular
cells. Immunofluorescence studies revealed kappa chains in the
droplets. With time, the kappa chains aggregated into crystal-
line bodies and produced a degenerative change in the tubular
cells. Functional studies revealed a 20-fold increase in total
protein excretion during the first 12 hours after injection. Most
of the protein excreted was kappa light chain, but about 30%
consisted of low-molecular-weight proteins; the latter probably
represented induction of tubular proteinuria. Sensitive tests of
proximal tubular function such as para-aminohippuric acid
extraction and maximal tubular reabsorptive capacity for glu-
cose and bicarbonate were not carried out. The authors suggest-
ed that approximately 80% of the kappa chain filtered was
reabsorbed by the proximal tubular cells and that the reabsorp-
tion of large amounts of kappa chain interfered with normal
tubular functions (Fig. 2).
In-vitro studies also have suggested that light-chain proteins
can interfere with normal proximal tubular function. Preuss and
coworkers incubated rabbit and rat renal cortical slices in light-
chain proteins obtained from the urine of patients with multiple
myeloma and demonstrated that the ability of the kidney slices
to transport PAH and to produce ammonium and glucose was
markedly compromised [117, 118]. The authors suggested that
light-chain proteins may play an important role in the proximal
tubular dysfunction in some patients with light-chain protein-
uria. McGeoch et al reported that light chains affect renal
transport by inhibiting the active transport enzyme sodium-
potassium ATPase [119]. The available evidence therefore
suggests that when excessive light chains are reabsorbed by the
proximal tubules, both morphologic and functional derange-
ment can result (Fig. 2).
Nephrotoxicity. A highly significant relationship exists be-
tween the presence of light-chain proteinuria and the develop-
ment of azotemia [102, 1201. Considerable experimental evi-
dence suggests that light-chain proteins are nephrotoxic [116—
119]. However, many patients have persistent light-chain pro-
teinuria with no impairment of renal function; thus some light-
chain proteins appear to be less nephrotoxic than others.
The difference in nephrotoxicity does not appear to be related
to the amount or duration of light-chain excretion, because
many patients do not develop renal insufficiency despite severe,
sustained light-chain proteinuria. Nephrotoxicity appears, at
least in part, to depend on the physical and chemical properties
of the light-chain proteins. The size of the light-chain proteins
as well as their degree of polymerization and glycosylation have
been suggested as possible determinants of nephrotoxicity, but
several studies suggest that the isoelectric point of the light-
chain protein is a particularly important determinant of its
nephrotoxicity [121, 1221. Clyne, Pesce, and Thompson isolated
light-chain proteins from 11 patients with multiple myeloma; the
light chains were then tested for acute nephrotoxicity in the
aciduric, hydropenic rat [121]. There was a highly significant
correlation between the acute renal functional deterioration and
the isoelectric points (pls) of the light-chain proteins. All rats
injected with light-chain proteins showed proximal tubular
droplets immunoreactive with light-chain proteins. However,
acute renal failure with intratubular casts in the distal convolut-
ed tubule, cortical collecting duct, and medullary collecting
duct was seen only in rats injected with light-chain proteins with
a p1 greater than 6.2. The casts observed were immunoreactive
with antisera to light chain. No casts were seen in rats injected
with light-chain proteins with pis less than 6.2. Coward et al
examined the relationship between the light-chain isoelectric
point and renal function in 23 patients with multiple myeloma
[122]. In these patients, light-chain isoelectric points correlated
with creatinine clearance. This finding suggests that the isoelec-
tric point is an important determinant of the nephrotoxic effect
of light-chain protein (Fig. 3). It is clear, however, that dehydra-
tion and aciduria increase nephrotoxicity. In the in-vivo experi-
ments with rats, hydration and alkalinization of urine prevented
renal failure and cast formation even in instances in which
nephrotoxic light-chain proteins with high pls were injected
[121].
Amyloidosis. The major protein component associated with
primary and myeloma-associated amyloidosis is known to be
derived from light chains. Most patients with amyloidosis have
light-chain proteins of the lambda type [16, 62]. Glenner and
colleagues showed a close similarity between the amino acid
sequence of the variable regions of light-chain proteins and that
of amyloid fibrils [123]. Subsequently it was shown that trypsin,
pepsin [124, 125] and lysosymal enzymes [1261 can convert
immunoglobulin light chains into fibrils with the appearance of
amyloid on electron microscopy. This fibrillar material deposits
in a a-pleated form in the kidneys and other organs.
Light-chain deposition disease. The precise mechanism of
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Fig. 3. Nephrotoxicity of light-chain proteins.
tissue precipitation of light-chain proteins is unclear. Ganeval et
al pointed out that patients with light-chain deposition disease
appear to produce abnormal light chains [23]. These abnormal
tight-chain proteins are glycosylated before being deposited in
the kidneys and other organs. Electron microscopic studies
reveal granular, nonfibrillar deposits (in contrast to the fibrillar
deposits of amyloidosis). It is of interest that most patients with
light-chain deposition disease have kappa light chains [231.
Questions and answers
DR. RAYMOND ENDRENY (Clinical Instructor, Brown Univer-
sity School of Medicine, Providence, Rhode Island): Is toluene-
sulfonic acid more sensitive than the conventional tests for
detecting light-chain protein?
DR. FANG: Toluene-sulfonic acid is similar to sulfasalicylic
acid in its sensitivity and specificity and it will detect the
presence of light-chain proteins only in concentrations in excess
of 100 mg/dl. There are again false positives with this test.
DR. JEROME P. KASSIRER: Can you elaborate on the histo-
pathology of the kidney in patients with proteinuria? How
specific is the finding of light chains in the kidney?
DR. FANG: Patients with tight-chain proteinuria can have a
variety of histopathologic lesions. In the proximal tubules,
crystalline deposits can be seen. Immunofluorescence studies
identify these crystals as light-chain proteins. Proximal tubular
dysfunction can occur in patients with these proximal tubular
lesions. Lesions also can be seen in the distal tubules in patients
with multiple myeloma and light-chain proteinuria. The most
unique finding is that of the "myeloma kidney," in which
laminated, glassy, eosinophilic casts appear in the distal tu-
bules. In the proximal and distal tubules, significant tubular
necrosis occurs, with associated interstitial inflammation, fibro-
sis and, occasionally, giant cell reaction. Presence of light
chains in the kidney usually reflects increased light-chain
production and excretion and is associated with lymphoproliler-
ative diseases.
DR. NIcoLAos E. MADIAS: Has any study examined the
handling of light-chain protein in relationship to renal function?
Can renal insufficiency lead to an increase in the normally
minute level of light-chains in the serum?
DR. FANG: Normally, minute amounts of free light chains are
produced and filtered. These are reabsorbed and metabolized
by the proximal tubular cells, as I mentioned earlier. With renal
insufficiency, light-chain clearance may be hampered. Howev-
er, the amount of free light chains in the serum is still exceeding-
ly low. Moreover, the light-chain proteins present are heteroge-
neous (mixed lambda and kappa light chains) and therefore are
unlikely to be mistaken for monoclonal gammopathy.
DR. JOHN T. HARRINGTON: Dr. Kassirer, would you give us a
brief follow-up on the patient you reported in 1976 [61]?
DR. KASSIRER: That interesting patient that Drs. Smithline,
Cohen, and I described had light-chain proteinuria with both
proximal and distal tubular dysfunction. Treatment with a short
course of meiphalan and prednisone reduced the light-chain
excretion and ameliorated the water-excreting defect, but it did
not affect the phosphaturia. Initially her osteomalacia pro-
gressed, but therapy with oral phosphate reversed this process.
Renal function remained normal, and when the patient died of a
perforated viscus 11 years after the onset of the first symptoms
of her nephropathy, she was found to have extensive amyloid-
osis, including in her kidneys. The initial renal biopsy had
shown minimal abnormalities and no amyloid.
DR. MADIAS: Why do 30% to 40% of patients with Walden-
strom's macroglobulinemia have light-chain proteinuria and
rarely suffer light-chain nephrotoxicity? Is this possibly related
to the isoelectric point of the involved light chains?
DR. FANG: To my knowledge, this issue has not been
addressed yet. Indeed, it would be interesting to see whether
light-chain proteins in patients with WaldenstrOm's macro-
globulinemia have low isoelectric points.
DR. HARRINGTON: Let's return to Dr. Madias' basic ques-
tion. Do all five lambda and four kappa chains have different
isoelectric points, and does this account for the variable neph-
rotoxicity of these substances?
DR. FANG: The studies looking at the relationship between
isoelectric points and nephrotoxicity did not examine the iso-
electric points of different subtypes of light-chain proteins.
DR. ANDREW LEVEY (Division of Nephrology, NEMC):
Should we alkalinize the urine of patients with myeloma? Is it a
sound recommendation?
DR. FANG: In experimental settings, alkalinization appears
helpful. Clyne et al injected into rats urinary light-chain proteins
obtained from patients with myeloma, and found that volume
depletion and aciduria predisposed the rats to acute renal failure
[121]. When the rats were hydrated and given a sodium bicar-
bonate load, acute renal failure was prevented. It is not clear in
this set of experiments whether correction of volume depletion
or correction of aciduria was more important.
DR. KASSIRER: You mentioned that one of the causes of acute
renal failure in myeloma is hyperuricemia. I've never seen an
example of severe hyperuricemia in myeloma causing acute
renal failure; neither have I ever found one in the literature. I
assume that therapy-induced severe hyperuricemia doesn't
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occur simply because the clone of cells is not very large and
because chemotherapy is simply not very effective.
DR. FANG: That is an important point. To my knowledge,
there has not been a case report of hyperuricemia causing uric
acid nephropathy in a patient with myeloma. Hyperuricemia
can develop in the course of chemotherapy, but patients are
usually hydrated and treated with allopurinol before chemo-
therapy is initiated.
DR. MADIAS: Is it possible for some patients with the Fanconi
syndrome to develop at least low-grade light-chain proteinuria
as a mere consequence of the underlying proximal tubular
dysfunction? If so, the light-chain proteinuria might be but one
of the manifestations of the Fanconi syndrome rather than its
cause.
DR. FANG: Patients with the Fanconi syndrome indeed can
have low-grade light-chain proteinuria. The quantity is usually
exceedingly low. More importantly, urinary immunoelectro-
phoresis reveals the heterogeneity of these light-chain proteins.
In light-chain proteinuria, the light chain proteins are present in
much higher concentrations and are monoclonal on immuno-
electrophoretic studies.
Reprint requests to Dr. L. Fang, Massachusetts General Hospital, 15
Parkman Street, Boston, Massachusetts, 02114, USA
References
1. JoNEs HB: Papers on chemical pathology: Prefaced by the Gui-
stonian lectures, read at the Royal College of Physicians, 1846.
Lancet 2:88—92, 1847
2. MACINTYRE W: Case of mollities and fragilitas ossium, accompa-
nied with urine strongly charged with animal matter. Med Chir Soc
33:211—232, 1850
3. MAACK T, JOHNSON V, KAU ST, FIGUEIREDE J, SIGULEM D:
Renal filtration, transport and metabolism of low molecular weight
proteins. A review. Kidney mt 16:251—270, 1979
4. CARONE FA, PETERSON DR: Hydrolysis and transport of small
peptides by the proximal tubules. Am J Physiol 238:F151-F158,
1980
5. TAN M, EPSTEIN W: Polymer formation during the degradation of
human light-chain and Bence Jones proteins by an extract of the
lysosomal fraction of normal human kidney. Immunochemistry
9:9—16, 1972
6. JENSEN K: Metabolism of Bence Jones proteins in non-myeloma
patients with normal renal function. Scand J Chem Lab Invest
25:281—289, 1970
7. FERMIN EA, JONSON CA, ECKEL RE, BERVIER GM: Renal
removal of low molecular weight proteins in myeloma and renal
transplant patients. J Lab Chem Med 83:681—694, 1974
8. STROBER W, WALDMANN TA: The role of the kidney in the
metabolism of plasma proteins. Nephron 13:35—66, 1974
9. WOCHNER RD, STROBER W, WALDMANN TA: The role of the
kidney in the catabolism of Bence Jones proteins and immuno-
globulin fragments. J Exp Med 126:207—221, 1967
10. JENSEN K: Metabolism of Bence Jones proteins in multiple
myeloma patients and in patients with renal disease. Scand J Clin
Lab Invest 26:13—21, 1970
11. PUTNAM FW, EASLEY CW, LYNN LT ET AL: The heat precipita-
tion of Bence-Jones proteins. I. Optimum conditions. Arch Bio-
chemBiophys 83:115—130, 1959
12. PERRY MC, KYLE RA: The clinical significance of Bence Jones
proteinuria. Mayo Clin Proc 50:234—238, 1975
13. MCLAUGHLIN H, HOBBS JR: Clinical significance of Bence Jones
proteinuria. Protides of the Biologic Fluids. Proceedings of the
20th Colloquium, edited by PETTERS H, Oxford, Pergamon Press,
1973, pp 251—254
14. SOLOMON A: Bence Jones proteins and light chains of immuno-
globulins. N Engi J Med 294: 17—23, 91—98, 1976
15. DAMMACO F, WALDENSTROM J: Serum and urine light-chain
levels in benign monoclonal and WaldenstrOm's macroglobulin-
emia. Clin Exp Immunol 3:911—921, 1968
16. ISOBE T, O55ERMAN EF: Patterns of amyloidosis and their associa-
tion with plasma cell dyscrasia, monoclonal immunoglobulins and
Bence Jones proteins. N Engl J Med 290:473—477, 1974
17. LINKE RP, TISCHENDORF FW, ZUCKER-FRANKLIN D: The forma-
tion of amyloid-like fibrils in vitro from Bence-Jones proteins of
the lambda I subclass. J Immunol 111:24—26, 1973
18. AZAR HA, HILL WT, OSSERMAN EF: Malignant lymphoma and
lymphatic leukemia associated with myeloma type serum. Am J
Med 23:239—249, 1957
19. SELIGMANN M, CLAUVEL J: Current views on immunoglobulin
abnormalities and B cell proliferations, in Advances in Nephrolo-
gy, edited by HAMBURGER J, CROSNIER J, GRUNFELD JP, MAX-
WELL MH, Chicago: Year Book Medical Publishers, 1978, pp 237—
289
20. BAHT JG, KERPEN HO, MURPHY PS, HoRowiTz U, VALDEN-
RAMA JH: Angioimmunoblastic lymphadenopathy, Bence Jones
proteinuria and acute renal failure. Arch Intern Med .141:1373—
1374, 1981
21. HOBBS JR. EVANS DJ, WRONG OM: Renal tubular obstruction by
mucoproteins from adenocarcinoma of pancreas. Br Med J 2:87—
89, 1974
22. IBANEZ ML, RUSSELL WO, ABORES-SAAVEDRA J, LAMPERFICO P,
WHITE EC, CLERK RL: Thyroid carcinoma: biologic behavior and
mortality. Cancer 19:1039—1052, 1966
23. GANEVAL D, NOEL LH, PREUD'HOMME J-L, DROZ D, GRUNFELD
J-P: Light-chain deposition disease: Its relation with AL-type
amyloidosis. Kidney Int 26:1—9, 1984
24. RANDALL RE, WILLIAMSON WC JR, MULLINAX F, TUNG MY,
STILL WJS: Manifestations of systemic light chain deposition. Am
JMed 60:293—299, 1976
25. GALLO GR, FEINER HD, KATZ LA, FELDMAN GM, CORRRA E,
CHUBA JV, BUXBAUM JN: Nodular glomerulopathy associated
with nonamyloidotic kappa light chain deposits and excess immu-
noglobulin light chain synthesis. Am J Pathol 99:621—632, 1980
26. GANEVAL D, NOEL LD, DROZ D, LEIBOWITCH J: Systemic
lambda light chain deposition in a patient with myeloma. Br Med J
282:681—683, 1981
27. CASE RECORDS OF TI-IF MASSACHUSETTS GENERAL HOSPITAL:
Case 1,1981. NEnglJMed3O4:33—43, 1981
28. HALLEN J: Discrete gammaglobulin (M-) components in serum:
Clinical study of 150 subjects without myelomatosis. Acta Med
Scand 426(suppl): 1—10, 1966
29. WILLIAMS RC JR, BAILLY RC, HOWE RB: Studies of "benign"
serum M-components. Am J Med Sci 257:275—279, 1969
30. KYLE RA, MALDONADO JE, BAYRD ED: Idiopathic Bence Jones
proteinuria—A distinct entity? Am J Med 55:222—226, 1973
31. PRENTISS RG: Multiple myeloma with diffuse skeletal involve-
ment: Case report. Milit Surgeon 80:294—296, 1937
32. WEICKER H, BRUCI-IER H, HUHNSTOCK K, MEISER J, PLUGGE H:
Papaproteinosen: Klinische, biochemische and morphologische
Verlaufsuntersuchungen. Dtsch Arch Kim Med 211:14—19, 1965
33. KYLE RA: Multiple myeloma: Review of 869 cases. Mayo Clin
Proc 50:29—40, 1975
34. LEVIN WC (ed): Symposium on myeloma. Arch Intern Med
135:27—76, 1975
35. STONE MJ, FRENKEL EP: The clinical spectrum of light-chain
myeloma: A study of 35 patients with special reference to the
occurrence of amyloidosis. Am J Med 58:601—619, 1975
36. BAYRD ED, HECK FJ: Multiple myeloma, a review of 83 proved
cases. JAMA 133:147—156, 1947
37. BROWNELL EG: Multiple myeloma, a review of 61 proved cases.
Arch Intern Med 95:699—722, 1955
38. CARSON CP, ACKERMAN LV, MALTBY JD: Plasma cell myeloma.
A clinical, pathologic and roentgenologic review of 90 cases. Am J
Clin Pathol 25:849—877, 1955
39. GLENCHUR H, ZINNEMAN HH, HALL WH: A review of 51 cases
of multiple myeloma. Arch Intern Med 103:173—187, 1959
40. FERGER BG, SQUIRES JW, SHELDON H: WaldenstrOm's macro-
globulinemia with generalized amyloidosis. Arch Intern Med
118:363—375, 1966
41. WALDENSTROM J: Macroglobulinemia. Adv Metab Dis 2:115—158,
1965
Light-chain nephropathy 591
42. MOREL-MAROGER L, BASCH A, DANON F, VERROUST P, RICHET
G: Pathology of the kidney in WaldenstrOm's macroglobulinemia.
NEnglJMed 283:123—129, 1970
43. MARTELO 0, SCHULTZ D, PARDO V, PEREZ-STABLE B: Immuno-
logically-mediated renal disease in Waldenstrom's macroglobulin-
emia. Am J Med 58:567—575, 1975
44. ENGLE RL JR, WALLIS LA: Multiple myeloma and the adult
Fanconi syndrome. Am J Med 22:5—18, 1957
45. SHORT IA, SMITH JP: Myelomatosis associated with glycosuna
and aminoaciduria. Scott Med J 4:89—93, 1959
46. COSTANZA DJ, SMOLLER M: Multiple myeloma and the Fanconi
syndrome. Am J Med 34: 125—133, 1963
47. DEDMON RE, WEST JH, SCHWARTZ TB: The adult Fanconi
syndrome: report of two cases, one with multiple myeloma. Med
Clin North Am 47:191—206, 1963
48. Hoar.i ME, KNAPP MS, PAGE FT, ETAL: Adult Fanconi syndrome
and multiple myelomatosis. J Gun Pathol 22:414—416, 1969
49. HEADLEY RN, KING JS JR, COOPER MR, ET AL: Multiple myelo-
ma presenting as adult Fanconi syndrome. C/in Chem 18:293—295,
1972
50. MALDONADO JE, VELOSA JA, KYLE RA, ET AL: Fanconi Syn-
drome in adults. Am J Med 58:354—364, 1975
51. WALKER BR, ALEXANDER F, TANNENBAUM PJ: Fanconi syn-
drome with renal tubular acidosis and light-chain proteinuria.
Nephron 8:103—107, 1971
52. FINKEL PN, KRONENBERG K, PESCE AJ, ET AL: Adult Fanconi
syndrome, amyloidosis and marked K-light-chain proteinuria.
Nephron 10:1—24, 1973
53. Medical Staff Conference: The clinical spectrum of Fanconi's
syndrome. Ca/if Med 108:225—231, 1968
54. LEE DBN, DRINKARD JP, ROSEN VJ: The adult Fanconi syn-
drome: Observations on etiology, morphology, renal function and
mineral metabolism in three patients. Medicine 51:107, 1972
55. HARRISON JF, BLAINEY JD: Adult Fanconi syndrome with mono-
clonal abnormality of immunoglobulin light chain. J Gun Pathol
20:42—48, 1967
56. SIROTA JH, HAMMERMAN D: Renal function studies in an adult
subject with the Fanconi syndrome. Am J Med 16:138, 1954
57. DEFRONZO RA, COOKE JR, HUMPHREY RL: Renal function in
patients with multiple myeloma. Medicine 57:151—166, 1978
58. RAWLINGS W JR, GRIFFIN J, DUFFY T, HUMPHREY R: Fanconi
Syndrome with lambda light chains in urine (letter). N Engi J Med
292:1351, 1975
59. GONICK HC: cited in Southern California Transplant Workshop.
Dial Transp 5:63, 1976
60. MACKENZIE MR, FUDENBERG HH: Macroblobulinemia. An anal-
ysis of 40 patients. Blood 39:874—889, 1972
61. SMITHLINE N, KASSIRER JP, COHEN ii: Light chain nephropathy.
Renal tubular dysfunction associated with light-chain proteinuna.
N Eng/ J Med 294:71—74, 1976
62. SILVA FG, PIRANI CL, MESA-TEJADA R, WILLIAMS G: The
kidneys in plasma cell dyscrasias. A review and clinico-pathologic
study of 50 patients. Progress in Surgical Pathology, vol 5, edited
by FENOGLIO C, WOLFF M, New York, Masson, 1982
63. LIMAS C, WRIGHT JR. MATSUZAKI M, CALKIN5 E: Amyloidosis
and multiple myeloma. Am J Med 54:166—173, 1973
64. FAHEY JL, CARBONE PP, ROWE DS, BACHMANN R: Plasma cell
myeloma with D myeloma protein. Am J Med 45:373—380, 1968
65. KYLE RA, BAYRD ED: Amyloidosis: Review of 236 cases. Medi-
cine 54:271—299, 1975
66. GLENNER GG, JERRY WD, I5ERKY G: Amyloidosis: Its nature and
pathogenesis. Sem Hematol 10:65—86, 1973
67. MOREL-MAROGER L, VERROUST P: Glomerular lesions in dyspro-
teinemias. Kidney mt 5:249—252, 1974
68. AVASTHI PS, ERICKSON DG, WILLIAMS RC JR, JUNG KSK:
Benign monoclonal gammaglobulinemia and glomerulonephritis.
Am J Med 62:324—329, 1977
69. MARTINEZ-MALDONADO M, YIUM J, SUKI WN, EKNOYAN G:
Renal complications in multiple myeloma: Pathophysiology and
some aspects of clinical management. J Chron Dis 24:221—237,
1971
70. GANEVAL D, CATHOMEN M, NOEL L-H, GRUNFELD J-P: Kidney
involvement in multiple myeloma and related disorders. Contrib
Nephrol 33:210—222, 1982
71. DEFRONZO RA, HUMPHREY RL, WRIGHT JR, COOKE CR: Acute
renal failure in multiple myeloma. Medicine 54:209—223, 1975
72. HEALY JK: Acute oliguric renal failure associated with multiple
myeloma. Report of three cases. BrMedJ 1:1126—1130, 1963
73. BRYAN CW, HEALY JK: Acute renal failure in multiple myeloma.
Am J Med 44:128—135, 1968
74. KJELDSBERG CR, HOLMAN RE: Acute renal failure in multiple
myeloma. J Urol 105:21—25, 1971
75. REES ED, WAUGH WH: Factors in renal failure of multiple
myeloma. Arch Intern Med 116:400—405, 1966
76. KYLE RA, ELVEBACKLR: Management and prognosis of multiple
myeloma. Mayo Clin Proc 51:751—760, 1976
77. EPSTEIN FH: Calcium and the kidney. Am J Med 45:700—714, 1968
78. BARTELS ED, BRUN GC, GAMMELTOFT A, GJORUB PA: Acute
anuria following intravenous pyelography in patients with myelo-
matosis. Acta Med Scand 150:297—302, 1954
79. MYHRE JR, BRODWALL EK, KNUTSEN SB: Acute renal failure
following intravenous pyelography in patients with myelomatosis.
Acta Med Scand 156:263—266, 1956
80. BRUDIGAN B, MOELLER J: Atypical plasmacytoma with severe
hypersensitivity reaction from perabrodil. Kim Wochenschr
35:280—284, 1957
81. KILLMAN SA, GJORUB S, THAYSEN JH: Fatal acute renal failure
following intravenous pyelography in patient with multiple myelo-
ma. Acta Med Scand 158:43—56, 1957
82. PERILLE PB, CONN HO: Acute renal failure after intravenous
pyelography in plasma cell myeloma. JAMA 167:2186—2189, 1958
83. FUNCK-BRETANO JL: The myeloma kidney. Rev Prat 9:1765—
1773, 1959
84. SCHEITLIN W, MARTZG, BRUNNER U: Acute renal failure follow-
ing intravenous pyelography in multiple myeloma. Schweiz Med
Wochenschr 90:84—87, 1960
85. SANCHEZ LM, DORNZ CA: Renal patterns in myeloma. Ann Intern
Med 52:44—54, 1960
86. LEUCUTrA T: Multiple myeloma and intravenous pyelography
(editorial). Am J Roent Rad Ther Nucl Med 85:187—189, 1961
87. MACALISTER CLO, ADDISON NV: Slowly deteriorating renal
function before pyelographic study. Br J Urol 33:141—148, 1961
88. CAUCHIE C: Les manifestations renales du myelome. J Urol
(Paris) 68:41—56, 1962
89. OLMERJ, CASANOVA P, MURATORE R, KNEBELMANN G: Dangers
de l'urographie intraveinueses dans les myelomes. J Urol (Paris)
68:84—89, 1962
90. BROWN M, BATTLE JD JR: Effect of urography on renal function
in patients with multiple myeloma. Can Med Assoc J 91:786—790,
1964
91. ROSENBAUM HD, LAPPATEJ, CAWEIN M: Adverse reaction of
intravenous urography in multiple myeloma. J Ky Med Assoc
63:426—427, 1965
92. GROSS M, MCDONALD H JR, WATERHOUSE K: Anuria following
urography with meglumine diatrizoate (renografin) in multiple
myeloma. Radiology 90:780—781, 1968
93. LASSER EC, LANG JH, ZAWALSKI ZA: Contrast media: myeloma
protein precipitates in urography. JAMA 198:945—947, 1966
94. MORGAN C JR, HAMMACK WJ: Intravenous urography in multiple
myeloma. N Engi J Med 275:77—79, 1966
95. Vx VA: Intravenous pyelography in multiple myeloma: A review
of 52 studies in 40 patients. Radiology 87:896—902, 1966
96. CWYNARSKI MT, SAXTON HM: Urography in myelomatosis. Br
MedJ 1:486, 1969
97. MYERS OH JR, WITTEN HM: Acute renal failure after excretory
urography in multiple myeloma. Am J Roent Rad Ther NucI Med
113:583—588, 1971
98. BALTZER G, JACOB H, ESSELBORN H, GASSEL WD: Contrast
media and renal function in multiple myeloma (author's transla-
tion). ROFO 129.2:208—211, 1978
99. KAPADIA SB: Multiple myeloma: a clinico-pathologic study of 62
consecutively autopsied cases. Medicine 29:380—392, 1980
100. VERROUST P, MERY J-P, MOREL-MAROGER L, CLAUVER JP,
RICHET G: Glomerular lesions in monoclonal gammopathies and
mixed essential cryoglobulinemias IgG-IgM. Adv Nephrol 1:161—
194, 1971
lOl. ARGANI I, KIPKIE OF: Macroglobulinemia nephropathy. Acute
renal failure in macroglobulinemia of Waldenström. Am J Med
592 Nephrology Forum
36:151—157, 1964
102. YIuM J, MARTINEZ-MALDONADO M, EKNOYAN G, SUKI WN:
Peritoneal dialysis in the treatment of renal failure in multiple
myeloma. South MedJ 64:1403—1405, 1971
103. JOHNSON WJ, KYLE RA, DAHLBERG PJ: Dialysis in the treatment
of multiple myeloma. Mayo Clin Proc 55:65—72, 1980
104. LAZARUS HM, ADELSTEIN DJ, HEIzIG RH, SMITH MC: Long-
term survival of patients with multiple myeloma and acute renal
failure at presentation. Am J Kidney Dis 2:521—525, 1983
105. FEEST TG, BURGE PS, COHEN SL: Successful treatment of
myeloma kidney by diuresis and plasmapheresis. Br MedJ 1:503—
504, 1976
106. LOCATELLI F, POZZI C, PEDRINI L, MAIw P, DIFILIPPO S. PONTI
R, COSTANZO R: Steroid pulses and plasmapheresis in the treat-
ment of acute renal failure in multiple myeloma. Proc Eur Dial
Transplant Assoc 17:690—694, 1980
107. MIsIANI R, REMUZZI G, BERTANIT, LIcINI R, LEVONI P, CRIPPA
A, MECCA G: Plasmapheresis in the treatment of acute renal
failure in multiple myeloma. Am J Med 66:684—689, 1979
108. SIEBERTH HG, GLOECKNER W, BORBERG H, FOHNLMEISTER J:
Plasma separation in Goodpasture syndrome and multiple myelo-
ma. Proc Eur Dial Transplant Assoc 16:528—532, 1979
109. GALTON, DAG, PETO R: Report on the first myelomatosis trial. I.
Analysis of presenting features of prognostic importance. Br J
Haematol 24:123—132, 1973
110. PIRANI CL, SILVA FG, APPEL GB: Tubulo-interstitial disease in
multiple myeloma and other non-renal neoplasias. Contemp Issues
Nephrol 11:287—334, 1984
111. OSSERMAN EF: Plasma cell myeloma. II. Clinical aspects. N Engi
J Med 261:1006—1014, 1959
112. LEECH SH, POLESKY HF, SHAPIRO FL: Chronic hemodialysis in
myelomatosis. Ann Intern Med 77:239—242, 1972
113. VAZIRI ND, GOLDMAN R, SCHULTZE RG, LEE DBN, ROSEN SM:
Maintenance hemodialysis in myeloma kidney disease. West J
Med 126:91—94, 1971
114. BROWN WW, HEBERT LA, PIERING WF, PISCIOTTA AV, LEMANN
J JR, GARANCIS JC: Reversal of chronic end-stage renal failure due
to myeloma kidney. Ann Intern Med 90:793—794, 1979
115. HUMPHREY RL, WRIGHT JR, ZACHARY JB, STERIOFF S, D-
FRONZO RA: Renal transplantation in multiple myeloma. A case
report. Ann Intern Med 83:651—653, 1975
116. CLYNE DH, BRENDSTRUP L, FIRST MR, PESCE AJ, FINKEL PN,
POLLAK yE, PIRANI CL: Renal effects of intraperitoneal kappa
chain injection. Induction of crystals in renal tubular cells. Lab
Invest 31:131—142, 1974
117. PREU5S HG, HAMMACK WJ, MURDAUGH HV: The effect of Bence
Jones proteins on the in vitro function of rabbit renal cortex.
Nephron 5:210—216, 1967
118. PREuss HG, WEISS FR, IAMMARINO RM, HAMMACK Wi, MUR-
DAUGH HV: Effects on rat kidney slice function in vitro of proteins
from the urines of patients with myelomatosis and nephrosis. Clin
Sd Mol Med 46:283—294, 1974
119. MCGEOCH J, SMITH JF, LEDINOHAM J, Ross B: Inhibition of
active-transport sodium-potassium ATPase by myeloma protein.
Lancet 2:17—18, 1978
120. CAUCHIE C, KENIS Y, POTULIEGE P, SMULDERS J, COMPEL CK,
LAMBERT PU: Les manifestations renales des dysglobulinemias. J
UrolNephrol 68:41—56, 1962
121. CLYNE DH, PESCE AJ, THOMPSON RE: Nephrotoxicity of Bence
Jones proteins in the rat: Importance of protein isoelectric point.
Kidney mt 16:345—352, 1979
122, COWARD RA, DELAM0RE 1W, MALLICK NP, ROBINSON EL: The
importance of urinary immunoglobulin light chain isoelectric point
(p1) in nephrotoxicity in multiple myeloma. Clin Sci 66:229—232,
1984
123. GLENNER GG, EIN D, EANES D, BLADEN HA, JERRY W, PAGE D:
The creation of amyloid fibrils from Bence Jones proteins in vitro.
Science 174:712—714, 1971
124. LINKE RP, ZUCKER-FRANKLIN D, FRANKLIN EC: Morphologic,
chemical and immunologic studies of amyloid-fibrils formed from
Bence Jones proteins by proteolysis. J Immunol 11:10—23, 1971
125, EPSTEIN WV, TAN M, WOOD IS: Formulation of amyloid fibrils in
vitro by action of human kidney lysosomal enzymes on Bence-
Jones proteins. fLab Gun Med 84:107—1 10, 1974
126. ZEMER D, PRAs M, SOHAN E, GAFUI J: Coichicine in familial
Meditenanean fever. N Engi J Med 294:170, 1976
